Clinical usefulness of FDG-PET/CT scan imaging in the management of posttransplant lymphoproliferative disease

Transplantation

Volumn 85, Issue 5, 2008, Pages 707-712

  Bianchi, Elena ^a   Pascual, Manuel ^a   Nicod, Marie ^a   Delaloye, Angelika Bischof ^a   Duchosal, Michel A ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Computed tomography; Positron emission tomography; Posttransplant lymphoproliferative disease

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; MYCOPHENOLIC ACID; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS; VINCRISTINE;

ADULT; ARTICLE; B CELL LYMPHOMA; CASE REPORT; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FOLLOW UP; HUMAN; HUMAN TISSUE; KIDNEY GRAFT; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REMISSION;

ADULT; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATIONS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 40849118174     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181661676     Document Type: Article

References (15)

1. LaCasce AS. Post-transplant lymphoproliferative disorders. Oncologist 2006; 11: 674.
2. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005; 56: 155.
3. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000; 36: 69.
4. Knoop C, Kentos A, Remmelink M, et al. Post-transplant lymphoproliferative disorders after lung transplantation: First-line treatment with rituximab may induce complete remission. Clin Transpl 2006; 20: 179.
5. Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: Coregistered FDG PET and CT at staging and restaging - Do we need contrast-enhanced CT? Radiology 2004; 232: 823.
6. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: Current applications and future directions. Radiology 2006; 238: 405.
7. McCormack L, Hany TI, Hubner M, et al. How useful is PET/CT imaging in the management of post-transplant lymphoproliferative disease after liver transplantation? Am J Transpl 2006; 6: 1731.
8. Bakker NA, Pruim J, de GW, van Son WJ, van der Jagt EJ, van Imhoff GW. PTLD visualization by FDG-PET: Improved detection of extranodal localizations. Am J Transpl 2006; 6: 1984.
9. Marom EM, McAdams HP, Butnor KJ, Coleman RE. Positron emission tomography with fluoro-2-deoxy-D-glucose (FDG-PET) in the staging of post transplant lymphoproliferative disorder in lung transplant recipients. J Thorac Imag 2004; 19: 74.
10. Bakker NA, van Imhoff GW, Verschuuren EA, van Son WJ. Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation. Transpl Int 2007; 20: 207.
11. Hernandez-Maraver D, Hernandez-Navarro F, Gomez-Leon N, et al. Positron emission tomography/computed tomography: Diagnostic accuracy in lymphoma. Br J Haematol 2006; 135: 293.
12. 18F]-FDG-PET(/CT) in initial staging and therapy monitoring. Eur J Radiol 2007; 63: 427.
13. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579.
14. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571.
15. Haddad E, Paczesny S, Leblond V, et al. Treatment of B- lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: A multicenter phase 1-2 clinical trial. Blood 2001; 97: 1590.